Therefore, these results indicated that RB, the RB-based mDC vaccine, and the RB-iDC vaccine increased the proportion of intrinsic tumour-specific CD8+ T cells and suggested a crucial role for tumour-specific CD8+ T cells in the generation of antitumour immunity. The gene discussed is CD8A; the disease is neoplasm.